How much did Alterity Therapeutics achieve in EBIT for the current year?
In the current year, Alterity Therapeutics has achieved an EBIT of -19.34 M AUD.
Alterity Therapeutics EBIT 2024
Alterity Therapeutics EBIT
-19.34 M AUD
Ticker
ATH.AX
ISIN
AU0000043945
WKN
A2PHDZ
In 2024, Alterity Therapeutics's EBIT was -19.34 M AUD, a 32.26% increase from the -14.62 M AUD EBIT recorded in the previous year.
The Alterity Therapeutics EBIT history
| YEAR | EBIT (undefined AUD) |
|---|---|
| 2024 | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
| 2012 | - |
| 2011 | - |
| 2010 | - |
| 2009 | - |
| 2008 | - |
| 2007 | - |
| 2006 | - |
| 2005 | - |
Alterity Therapeutics Revenue, EBIT, Net Income AU0000043945 · A2PHDZ
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Alterity Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Alterity Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Alterity Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Alterity Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Alterity Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Alterity Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Alterity Therapeutics’s growth potential.
Alterity Therapeutics Revenue, EBIT and net profit per share
| Date | Alterity Therapeutics Revenue | Alterity Therapeutics EBIT | Alterity Therapeutics Net Income |
|---|---|---|---|
| 2024 | 268,420 undefined | -19.34 M undefined | -19.12 M undefined |
| 2023 | 16,440 undefined | -14.62 M undefined | -13.81 M undefined |
| 2022 | 2,500 undefined | -15.95 M undefined | -12.85 M undefined |
| 2021 | 20,680 undefined | -15.37 M undefined | -15.31 M undefined |
| 2020 | 17,120 undefined | -13.91 M undefined | -13.46 M undefined |
| 2019 | 108,540 undefined | -12.69 M undefined | -12.34 M undefined |
| 2018 | 201,170 undefined | -7.99 M undefined | -8.27 M undefined |
| 2017 | 132,400 undefined | -6.88 M undefined | -7.54 M undefined |
| 2016 | 142,660 undefined | -8.59 M undefined | -7.73 M undefined |
| 2015 | 176,840 undefined | -17.01 M undefined | -5.89 M undefined |
| 2014 | 360,000 undefined | -20.37 M undefined | -13.33 M undefined |
| 2013 | 150,000 undefined | -12.27 M undefined | -7.79 M undefined |
| 2012 | 190,000 undefined | -5.31 M undefined | -5.24 M undefined |
| 2011 | 160,000 undefined | -6.27 M undefined | -6.43 M undefined |
| 2010 | 220,000 undefined | -4.9 M undefined | -4.91 M undefined |
| 2009 | 430,000 undefined | -8.29 M undefined | -7.53 M undefined |
| 2008 | 490,000 undefined | -12.71 M undefined | -13.56 M undefined |
| 2007 | 510,000 undefined | -10.99 M undefined | -11.14 M undefined |
| 2006 | 1.05 M undefined | -11.94 M undefined | -11.72 M undefined |
| 2005 | 2.65 M undefined | -12.79 M undefined | -25.01 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2005 | 2.65 M AUD | -12.79 M AUD | -25.01 M AUD |
| 2006 | 1.05 M AUD | -11.94 M AUD | -11.72 M AUD |
| 2007 | 510,000 AUD | -10.99 M AUD | -11.14 M AUD |
| 2008 | 490,000 AUD | -12.71 M AUD | -13.56 M AUD |
| 2009 | 430,000 AUD | -8.29 M AUD | -7.53 M AUD |
| 2010 | 220,000 AUD | -4.9 M AUD | -4.91 M AUD |
| 2011 | 160,000 AUD | -6.27 M AUD | -6.43 M AUD |
| 2012 | 190,000 AUD | -5.31 M AUD | -5.24 M AUD |
| 2013 | 150,000 AUD | -12.27 M AUD | -7.79 M AUD |
| 2014 | 360,000 AUD | -20.37 M AUD | -13.33 M AUD |
| 2015 | 176,840 AUD | -17.01 M AUD | -5.89 M AUD |
| 2016 | 142,660 AUD | -8.59 M AUD | -7.73 M AUD |
| 2017 | 132,400 AUD | -6.88 M AUD | -7.54 M AUD |
| 2018 | 201,170 AUD | -7.99 M AUD | -8.27 M AUD |
| 2019 | 108,540 AUD | -12.69 M AUD | -12.34 M AUD |
| 2020 | 17,120 AUD | -13.91 M AUD | -13.46 M AUD |
| 2021 | 20,680 AUD | -15.37 M AUD | -15.31 M AUD |
| 2022 | 2,500 AUD | -15.95 M AUD | -12.85 M AUD |
| 2023 | 16,440 AUD | -14.62 M AUD | -13.81 M AUD |
| 2024 | 268,420 AUD | -19.34 M AUD | -19.12 M AUD |
Alterity Therapeutics stock margins AU0000043945 · A2PHDZ
The Alterity Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Alterity Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Alterity Therapeutics.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Alterity Therapeutics's sales revenue. A higher gross margin percentage indicates that the Alterity Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Alterity Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Alterity Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Alterity Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Alterity Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Alterity Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Alterity Therapeutics Margin History
| Alterity Therapeutics Gross margin | Alterity Therapeutics Profit margin | Alterity Therapeutics EBIT margin | Alterity Therapeutics Profit margin |
|---|---|---|---|
| 2024 | 22,110.71 % | -7,204.58 % | -7,124.45 % |
| 2023 | 22,110.71 % | -88,940.45 % | -83,981.27 % |
| 2022 | 190,200.01 % | -638,144.43 % | -513,882.4 % |
| 2021 | 19,245.65 % | -74,328.35 % | -74,029.74 % |
| 2020 | -2,061.92 % | -81,265.07 % | -78,602.81 % |
| 2019 | 22,110.71 % | -11,688.68 % | -11,367.08 % |
| 2018 | 22,110.71 % | -3,974.19 % | -4,108.83 % |
| 2017 | 22,110.71 % | -5,197.78 % | -5,696.43 % |
| 2016 | 22,110.71 % | -6,019.07 % | -5,418.16 % |
| 2015 | 22,110.71 % | -9,619.02 % | -3,327.91 % |
| 2014 | 22,110.71 % | -5,658.33 % | -3,702.78 % |
| 2013 | 22,110.71 % | -8,180 % | -5,193.33 % |
| 2012 | 22,110.71 % | -2,794.74 % | -2,757.89 % |
| 2011 | 22,110.71 % | -3,918.75 % | -4,018.75 % |
| 2010 | 22,110.71 % | -2,227.27 % | -2,231.82 % |
| 2009 | 22,110.71 % | -1,927.91 % | -1,751.16 % |
| 2008 | 22,110.71 % | -2,593.88 % | -2,767.35 % |
| 2007 | 22,110.71 % | -2,154.9 % | -2,184.31 % |
| 2006 | 22,110.71 % | -1,137.14 % | -1,116.19 % |
| 2005 | 22,110.71 % | -482.64 % | -943.77 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2005 | 22,110.71 % | -482.64 % | -943.77 % |
| 2006 | 22,110.71 % | -1,137.14 % | -1,116.19 % |
| 2007 | 22,110.71 % | -2,154.9 % | -2,184.31 % |
| 2008 | 22,110.71 % | -2,593.88 % | -2,767.35 % |
| 2009 | 22,110.71 % | -1,927.91 % | -1,751.16 % |
| 2010 | 22,110.71 % | -2,227.27 % | -2,231.82 % |
| 2011 | 22,110.71 % | -3,918.75 % | -4,018.75 % |
| 2012 | 22,110.71 % | -2,794.74 % | -2,757.89 % |
| 2013 | 22,110.71 % | -8,180 % | -5,193.33 % |
| 2014 | 22,110.71 % | -5,658.33 % | -3,702.78 % |
| 2015 | 22,110.71 % | -9,619.02 % | -3,327.91 % |
| 2016 | 22,110.71 % | -6,019.07 % | -5,418.16 % |
| 2017 | 22,110.71 % | -5,197.78 % | -5,696.43 % |
| 2018 | 22,110.71 % | -3,974.19 % | -4,108.83 % |
| 2019 | 22,110.71 % | -11,688.68 % | -11,367.08 % |
| 2020 | -2,061.92 % | -81,265.07 % | -78,602.81 % |
| 2021 | 19,245.65 % | -74,328.35 % | -74,029.74 % |
| 2022 | 190,200.01 % | -638,144.43 % | -513,882.4 % |
| 2023 | 22,110.71 % | -88,940.45 % | -83,981.27 % |
| 2024 | 22,110.71 % | -7,204.58 % | -7,124.45 % |
Alterity Therapeutics Aktienanalyse
What does Alterity Therapeutics do?
Alterity Therapeutics Ltd is an Australian company specializing in the discovery and development of therapeutics for neurodegenerative diseases. The company's history dates back to 1997 when it was established under the name Prana Biotechnology Limited. Alterity Therapeutics' business model is based on the research of protein aggregates responsible for neurodegenerative diseases. The company primarily focuses on developing drugs targeting the breakdown of these protein aggregates to minimize the effects of diseases such as Parkinson's, Alzheimer's, and Huntington's. The company has several divisions specializing in various aspects of product development, including preclinical research, clinical development, and commercial marketing. Alterity Therapeutics has several products in various stages of development. One of its leading products is PBT434, a drug that aims to prevent protein aggregates in the brain and target the treatment of Parkinson's disease. The drug has already been tested in clinical trials and has shown promising results. In addition to PBT434, the company also has other promising drugs in development, including PBT519, targeting the treatment of Alzheimer's disease, and PBT2, targeting the treatment of Huntington's disease. Alterity Therapeutics aims to minimize the impact of neurodegenerative diseases and improve the quality of life for millions of patients worldwide. The company collaborates with leading medical and academic institutions to develop innovative therapeutics that meet the needs of patients and clinicians. Overall, Alterity Therapeutics offers a promising pipeline of drugs that could play a significant role in the treatment of neurodegenerative diseases. The company has become a major player in the industry and has the potential to make a significant impact in the fight against these serious illnesses. Alterity Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Alterity Therapeutics's EBIT
Alterity Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Alterity Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Alterity Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Alterity Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Alterity Therapeutics stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Alterity Therapeutics.
How has the EBIT of Alterity Therapeutics developed in recent years?
The EBIT of Alterity Therapeutics has increased by 32.258% increased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Alterity Therapeutics?
The EBIT of Alterity Therapeutics is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Alterity Therapeutics pay?
Over the past 12 months, Alterity Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Alterity Therapeutics is expected to pay a dividend of 0 AUD.
What is the dividend yield of Alterity Therapeutics?
The current dividend yield of Alterity Therapeutics is .
When does Alterity Therapeutics pay dividends?
Alterity Therapeutics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Alterity Therapeutics?
Alterity Therapeutics paid dividends every year for the past 0 years.
What is the dividend of Alterity Therapeutics?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Alterity Therapeutics located?
Alterity Therapeutics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Alterity Therapeutics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Alterity Therapeutics from 9/26/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.
When did Alterity Therapeutics pay the last dividend?
The last dividend was paid out on 9/26/2024.
What was the dividend of Alterity Therapeutics in the year 2023?
In the year 2023, Alterity Therapeutics distributed 0 AUD as dividends.
In which currency does Alterity Therapeutics pay out the dividend?
The dividends of Alterity Therapeutics are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Alterity Therapeutics
Our stock analysis for Alterity Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Alterity Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Alterity Therapeutics Revenue
- Alterity Therapeutics Net Income
- Alterity Therapeutics P/E
- Alterity Therapeutics P/S
- Alterity Therapeutics EBIT
- Alterity Therapeutics Dividend
- Alterity Therapeutics Stocks
- Alterity Therapeutics Market capitalization
- Alterity Therapeutics Debt
- Alterity Therapeutics Liabilities
- Alterity Therapeutics Equity
- Alterity Therapeutics AAQS
- Alterity Therapeutics Employees
- Alterity Therapeutics ROE
- Alterity Therapeutics ROA
- Alterity Therapeutics ROCE
